Today: 4 April 2026
Browse Category

Stock Market 24 October 2025

Billionaire Larry Ellison’s Fortune Plummets: Oracle Share Slump Wipes Out $24B

Billionaire Larry Ellison’s Fortune Plummets: Oracle Share Slump Wipes Out $24B

Oracle shares fell 7% on Oct. 17 and nearly 5% on Oct. 20, erasing about $38 billion from Larry Ellison’s net worth. The stock closed near $280 on Oct. 23, down from September highs but still up roughly 70% year-to-date. Ellison remains the world’s second-richest person at $336–351 billion. Analysts’ price targets for Oracle range widely, with some citing risks tied to its AI rollout.
24 October 2025
Microsoft Stock Soars on AI and Cloud Frenzy – Analysts Eye $600+ Price Targets

Microsoft Stock Soars on AI and Cloud Frenzy – Analysts Eye $600+ Price Targets

Microsoft shares closed near $520, up 25% year-to-date, with a market cap approaching $3.8 trillion. Azure cloud revenue jumped 39% last quarter, outpacing AWS and Google Cloud. Wall Street remains bullish, with 32 of 34 analysts rating MSFT a “Buy” and a 12-month price target near $620–630. Microsoft reports Q1 FY2026 results on Oct. 29, with analysts expecting continued double-digit growth.
Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

RVPH shares closed at $0.57 on Oct 24 after a volatile month, swinging between $0.26 and $0.84. The stock surged 28% on Oct 23 following recent Phase 3 trial results for brilaroxazine and news of an upcoming FDA meeting. Reviva raised about $19 million this year to fund its CNS pipeline. Analyst targets average $6.25, implying a potential 1,000% upside.
AMD Stock Skyrockets on AI Mega-Deals – Is $300 Next?

AMD Stock Skyrockets on AI Mega-Deals – Is $300 Next?

AMD shares jumped 34% on Oct. 6 after announcing major AI GPU deals with OpenAI and Oracle, adding $80 billion in market value. The stock is up about 80–95% year-to-date, reaching all-time highs near $238 before settling at $235 by Oct. 23. Analysts raised price targets to as high as $310. Q2 2025 revenue rose 32% to $7.69 billion, with full-year sales guidance near $33 billion.
Genenta Science Stock Skyrockets on Strategic Gene-Therapy Alliance – Is a $25 Price Target Next?

Genenta Science Stock Skyrockets on Strategic Gene-Therapy Alliance – Is a $25 Price Target Next?

Genenta Science shares surged over 300% in early trading Oct. 24 after announcing an expanded partnership with Anemocyte to develop off-the-shelf lentiviral vector plasmid DNA for cell therapies. The company’s lead candidate Temferon showed a 29% two-year survival rate in glioblastoma patients, more than double standard care. Net loss narrowed to €3.83M in H1 2025. Analyst targets average $22.73, far above current prices.
Plug Power (PLUG) Stock Skyrockets 170% on Hydrogen Hype – Can It Last?

Plug Power (PLUG) Stock Skyrockets 170% on Hydrogen Hype – Can It Last?

Plug Power shares traded near $2.88 on Oct. 23, up about 170% since early September. The company secured a 1 GW electrolyzer order from Fortescue and delivered its first 10 MW unit to Galp’s Portugal project. Plug raised $370 million through warrant exercises on Oct. 8. Founder/CEO Andy Marsh will move to Executive Chair in 2026, with José Luis Crespo set to become CEO.
IonQ (INBX) Stock Soars on Quantum Breakthrough and $2B Deal – Bubble or Next Big Thing?

IonQ (INBX) Stock Soars on Quantum Breakthrough and $2B Deal – Bubble or Next Big Thing?

IonQ stock surged to a record near $82 in mid-October 2025, then dropped about 25% to close at $59.40 on Oct. 23 after heavy trading and news of possible U.S. government investment. A $2 billion equity deal and a quantum computing milestone fueled volatility. Wall Street targets range from $32 to $100, with consensus in the mid-$50s. IonQ will report Q3 results on Nov. 5.
CrowdStrike (CRWD) Stock Soars on AI Cybersecurity Boom — Record Highs

CrowdStrike (CRWD) Stock Soars on AI Cybersecurity Boom — Record Highs

CrowdStrike closed at $521.98 on Oct. 23, just below its all-time high, after rising nearly 40% year-to-date. Q2 FY2026 revenue reached $1.17 billion, up 21% year-over-year, with EPS of $0.93, both beating estimates. The company acquired Onum for $290 million and launched new AI security features. About 28 of 48 analysts rate CRWD a Buy, with average price targets near $496.
Palantir-Lumen AI Deal Sparks Stock Rally – CEO Warns of “Arms Race”

Palantir-Lumen AI Deal Sparks Stock Rally – CEO Warns of “Arms Race”

Lumen will invest over $200 million in Palantir under a multi-year partnership pairing Palantir’s AI platform with Lumen’s network infrastructure, both firms confirmed Oct. 23. Lumen shares jumped about 10% on the news, while Palantir stock has surged over 2,600% since early 2023. The deal marks a shift for both companies toward enterprise AI services. Lumen reports Q3 earnings Oct. 30; Palantir reports Nov. 3.
Rocket Companies Stock Blasts Off After $14B Mega-Merger – Will RKT Keep Soaring?

Rocket Companies Stock Blasts Off After $14B Mega-Merger – Will RKT Keep Soaring?

Rocket Companies closed a $14.2 billion acquisition of Mr. Cooper Group on Oct. 1, the largest mortgage merger to date. RKT stock trades near $17, up about 80% year-to-date but below its early October high of $22.56. Shares have rallied 50% since the merger was announced in March, with short interest at 57%. Q3 earnings are due Oct. 30, with analysts expecting EPS of $0.04, down 50% year-over-year.
American Airlines Lifts Profit Outlook, AAL Stock Rockets – Travel Boom or Turbulence Ahead?

American Airlines Lifts Profit Outlook, AAL Stock Rockets – Travel Boom or Turbulence Ahead?

American Airlines raised its 2025 profit outlook to $0.65–$0.95 EPS, up from a prior forecast of up to a $0.20 loss. Shares jumped 6% to $12.77 on Thursday. Third-quarter revenue hit a record $13.7 billion, while adjusted earnings showed a smaller-than-expected loss at -$0.17 per share. Premium cabin sales and cost controls offset flat overall revenue.
24 October 2025
Inhibrx Biosciences Stock Soars on Breakthrough Cancer Trial News

Inhibrx Biosciences Stock Soars on Breakthrough Cancer Trial News

Inhibrx’s ozekibart cut risk of progression or death by 52% in Phase 2 chondrosarcoma trial, doubling median progression-free survival to 5.52 months versus placebo. Shares of INBX jumped about 70% intraday and closed at $28.36 on Oct. 23, then surged another 75–80% after hours. Management plans a BLA filing in Q2 2026. Ozekibart also showed high response rates in colorectal and Ewing sarcoma cohorts.
Uranium Boom Propels Denison Mines (DNN) to New Highs as Analysts Weigh Rally

Denison Mines (DNN) Rides Uranium Boom as Wheeler River Advances – What’s Next?

Denison Mines shares more than doubled in 2025, reaching multi-year highs as uranium prices hit $80–$83 per pound. The company’s Wheeler River project secured key provincial permits and awaits a federal license by December. Denison restarted uranium production for the first time in 15 years and raised $345 million for growth. All five brokerages covering Denison rate the stock a “Buy” or “Outperform.”
Incredible Rally: Bitfarms (BITF) Stock Jumps 148% YTD Amid Crypto Boom & AI Pivot

Bitfarms (BITF) Stock Whipsaws as Bitcoin Hits Record High, $500M AI Pivot Fuels Rally – What’s Next?

Bitfarms shares traded near $4.10 on Oct. 24 after plunging 40% from a 52-week high of $6.20 reached Oct. 14, tracking sharp swings in Bitcoin prices. The company raised $588 million this month to fund a new HPC/AI campus in Pennsylvania and announced CFO Jeff Lucas will retire Oct. 27, replaced by Jonathan Mir. Bitfarms remains unprofitable, posting a $29 million Q2 loss on $78 million revenue.
Opendoor’s Wild 2025 Ride: Meme-Stock Surge, Crypto Pivot & Housing Hopes – What’s Next for OPEN?

Opendoor’s 1600% Meme-Stock Rally Meets Reality – New CEO, Crypto Hype & Housing Woes Collide

Opendoor shares surged from under $1 to over $10 in 2025, driven by retail hype, before settling near $7 in late October. The company named Kaz Nejatian as CEO and signaled plans for up to 85% layoffs. Q2 revenue rose 5% to $1.6 billion, but Q3 sales are forecast to fall by half. Most analysts rate the stock a “Sell,” with price targets far below current levels.
Quantum Gold Rush: D-Wave (QBTS) Stock Rockets on Government Funding Hopes and Breakthrough Deals

Quantum Gold Rush: D-Wave (QBTS) Stock Rockets on Government Funding Hopes and Breakthrough Deals

D-Wave’s share price surged nearly 3,000% in the past year, peaking at $46.75 on Oct. 15 before dropping to $27.30 and rebounding to $31.06 after reports of possible U.S. government equity deals with quantum firms. The company announced a €10 million sale of its Advantage2 system in Europe and posted first-half 2025 revenue of $18 million against a Q2 GAAP loss of $167 million. Trading volumes remain extremely high.
Tesla and Nokia Stocks Soar on EV Deliveries and 5G Deal Frenzy – What’s Next for Investors?

Tesla and Nokia Stocks Soar on EV Deliveries and 5G Deal Frenzy – What’s Next for Investors?

Tesla posted record Q3 revenue of $28.1 billion and delivered about 497,000 vehicles as buyers rushed to secure expiring U.S. tax credits. Higher costs and lower carbon-credit income cut profits, with EPS at $0.50 versus $0.55 expected. Tesla shares fell around 4% after hours on Oct. 22. As of Oct. 23, TSLA closed at $449.

Stock Market Today

  • The Renewables Infrastructure Group (LON:TRIG) Shares Dip Below 200-Day Moving Average
    April 4, 2026, 2:03 AM EDT. The Renewables Infrastructure Group Limited (LON:TRIG) fell below its 200-day moving average of 70.73 GBX, trading as low as 64 GBX on Friday. Shares last exchanged at 66.22 GBX with volume nearing 19.9 million. The firm, valued at £1.58 billion with a negative P/E ratio of -12.26, saw insider buying including 22,000 shares by Tove Feld and 40,000 by John Whittle recently. TRIG, listed on the FTSE 250 and focused on renewable energy infrastructure across the UK and Europe, aims to deliver capital growth and steady income tied to inflation. Despite the dip, analysts maintain a Buy rating. Insiders hold a minimal 0.03% stake.
Go toTop